Ayunova Pharmaceutical LLP

CAPNEA Sterile Oral Solution contains Caffeine Citrate, a central nervous system stimulant used primarily in the management of apnea of prematurity in neonatal patients. It helps stimulate the respiratory center, increases minute ventilation, and reduces episodes of apnea. The formulation is a sterile, ready-to-use oral solution intended strictly for oral administration under medical supervision.

Each ml contains:

• Caffeine Citrate IP – 20 mg
  (Equivalent to Caffeine 10 mg)

• Sterile aqueous base – q.s.

• Dosage Form: Sterile oral solution

CAPNEA Oral Solution is indicated for:

• Treatment of apnea of prematurity in preterm neonates

• Respiratory stimulation in neonatal intensive care settings

• For oral use only

• Dosage and duration as prescribed by a neonatologist or registered medical practitioner

• Administer using calibrated oral syringe or dropper

• Standard therapy for apnea of prematurity

• Sterile, ready-to-use oral formulation

• Accurate dosing for neonatal care

• Suitable for NICU and hospital use

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 20mg/ml

Botulinum Toxin Type A (Ph. Eur.) 200 Units is a purified neurotoxin derived from Clostridium botulinum, used for therapeutic and aesthetic applications. It works by blocking acetylcholine release at neuromuscular junctions, resulting in temporary muscle relaxation. This product is widely used in neurology, dermatology, and cosmetic medicine for treating spasticity, focal dystonias, hyperhidrosis, and facial wrinkles. The formulation meets European Pharmacopoeia (Ph. Eur.) standards.

Each vial contains:

• Botulinum Toxin Type A (Ph. Eur.) – 200 Units

• Stabilizers and excipients – q.s. (as per Ph. Eur. guidelines)

• Reconstitute with sterile saline prior to administration

Botulinum Toxin Type A 200 Units is indicated for:

• Therapeutic uses:

  • Cervical dystonia and other focal dystonias

  • Spasticity in adults and children

  • Chronic migraine prophylaxis

  • Hyperhidrosis (excessive sweating)

• Aesthetic uses:

  • Temporary reduction of facial wrinkles (glabellar lines, forehead lines, crow’s feet)

  • Muscle contouring for cosmetic improvement

• Administered via intramuscular or intradermal injection by qualified healthcare professionals only

• Dose and injection site depend on clinical indication and patient condition

• Reconstitute with sterile saline immediately before use

• Follow aseptic techniques and manufacturer’s instructions

• Store unreconstituted vials at 2–8°C, protected from light

• Do not freeze

• Use reconstituted solution within 24 hours or as per manufacturer instructions

• Single-use vial

• Strength: 200 Units per vial

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 100000
• Delivery Time: 10days
• Packaging Details: 200 units

Somatropin Genotropin® 36 IU GoQuick Injection contains recombinant human growth hormone (r-hGH) indicated for the treatment of growth hormone deficiency and growth disorders in children and adults. The GoQuick® prefilled pen offers a convenient, ready-to-use system with accurate dose delivery for subcutaneous self-administration under medical supervision. Genotropin helps promote linear growth in children and supports metabolic, musculoskeletal, and body composition benefits in adults.

Each GoQuick prefilled pen contains:

• Somatropin (recombinant human growth hormone) – 36 IU

• Excipients and stabilizers – q.s.

Pediatric Indications

• Growth hormone deficiency (GHD)

• Turner syndrome

• Chronic renal insufficiency–associated growth failure

• Small for gestational age (SGA) with failure to catch up

• Prader-Willi syndrome (with growth failure)

Adult Indications

• Adult growth hormone deficiency

• Growth hormone insufficiency following pituitary disease or surgery

• Subcutaneous injection only

• Dose individualized according to age, body weight, and clinical response

• Administered using the Genotropin GoQuick® prefilled pen

• Use strictly under endocrinologist supervision

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• After first use, store as per manufacturer’s instructions

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 36iu

Botulinum Toxin Type A Injection 100 Units is a sterile, purified neurotoxin preparation used for therapeutic and aesthetic applications under strict medical supervision. It works by temporarily blocking nerve signals to targeted muscles, helping in the management of various neuromuscular and glandular disorders. The injection is intended for use by trained healthcare professionals only.

• Active Ingredient:
  Botulinum Toxin Type A – 100 Units

• Excipients:
  q.s. (as per formulation)

• Dosage Form:
  Sterile Lyophilized Powder for Injection

Botulinum Toxin Type A Injection is commonly used for:

• Management of muscle spasticity

• Treatment of cervical dystonia

• Blepharospasm and hemifacial spasm

• Chronic migraine (as prescribed)

• Hyperhidrosis (excessive sweating)

• Other neuromuscular conditions as advised by a physician

• Aesthetic procedures such as reduction of facial wrinkles (by trained professionals)

• Administered via intramuscular or intradermal injection

• Dosage and injection sites depend on indication and patient condition

• To be reconstituted and administered only by qualified medical professionals

• Store at 2°C to 8°C (Refrigerated)

• Do not freeze

• Protect from light

• Use reconstituted solution within recommended time

• Prescription drug – use only under medical supervision

• Not to be used in patients with known hypersensitivity to botulinum toxin

• Use with caution in patients with neuromuscular disorders

• Not recommended during pregnancy or breastfeeding unless clearly advised by a doctor

• Single vial containing 100 Units

• Supplied with secure outer packaging to maintain sterility

• Manufactured in compliance with GMP guidelines

• Sterility and potency tested as per pharmacopeial standards

• India

Additional Information:

• Production Capacity: 200000
• Delivery Time: 10days
• Packaging Details: 100 UNITS

Botulinum Toxin Type A (Ph. Eur.) 50 Units is a purified neurotoxin produced by Clostridium botulinum, used for both therapeutic and aesthetic applications. It works by blocking the release of acetylcholine at neuromuscular junctions, resulting in temporary muscle relaxation. This product is widely used in neurology, dermatology, and cosmetic medicine for treating muscle hyperactivity, spasticity, and wrinkles. The preparation complies with European Pharmacopoeia (Ph. Eur.) standards.

Each vial contains:

• Botulinum Toxin Type A (Ph. Eur.) – 50 Units

• Stabilizers and excipients – q.s. (as per Ph. Eur. guidelines)

• Reconstitute with sterile saline prior to administration

Botulinum Toxin Type A 50 Units is indicated for:

• Therapeutic uses:

  • Focal dystonias (e.g., cervical dystonia)

  • Spasticity in adults and children

  • Chronic migraine prophylaxis

  • Hyperhidrosis (excessive sweating)

• Aesthetic uses:

  • Temporary reduction of facial wrinkles (glabellar lines, crow’s feet, forehead lines)

  • Contouring of facial muscles for cosmetic improvement

• Administered via intramuscular or intradermal injection by trained medical professionals only

• Dose and injection site depend on the clinical indication and patient condition

• Reconstitute with sterile saline immediately before use

• Follow aseptic techniques and manufacturer’s instructions

• Store unreconstituted vials at 2–8°C, protected from light

• Do not freeze

• Use reconstituted solution within the recommended time (usually 24 hours)

• Single-use vial

• Strength: 50 Units per vial

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 50 Units

Botulinum Toxin Type A (Ph. Eur.) 100 Units is a purified neurotoxin produced by Clostridium botulinum, used for both therapeutic and aesthetic applications. It works by blocking acetylcholine release at neuromuscular junctions, resulting in temporary muscle relaxation. This product is widely used in neurology, dermatology, and cosmetic medicine for treating muscle hyperactivity, spasticity, and facial wrinkles. The preparation meets European Pharmacopoeia (Ph. Eur.) standards.

Each vial contains:

• Botulinum Toxin Type A (Ph. Eur.) – 100 Units

• Stabilizers and excipients – q.s. (as per Ph. Eur. guidelines)

• Reconstitute with sterile saline prior to administration

Botulinum Toxin Type A 100 Units is indicated for:

• Therapeutic uses:

  • Focal dystonias (e.g., cervical dystonia)

  • Spasticity in adults and children

  • Chronic migraine prophylaxis

  • Hyperhidrosis (excessive sweating)

• Aesthetic uses:

  • Temporary reduction of facial wrinkles (glabellar lines, forehead lines, crow’s feet)

  • Contouring of facial muscles for cosmetic purposes

• Administered via intramuscular or intradermal injection by qualified healthcare professionals

• Dose and injection site depend on the clinical indication and patient condition

• Reconstitute with sterile saline immediately before use

• Follow aseptic techniques and manufacturer’s instructions

• Store unreconstituted vials at 2–8°C, protected from light

• Do not freeze

• Use reconstituted solution within the recommended time (usually 24 hours)

• Single-use vial

• Strength: 100 Units per vial

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10DAYS
• Packaging Details: 100 Units

Linezolid (Lyophilized) for Injection BP

Linezolid for Injection BP is a synthetic oxazolidinone antibiotic used for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

Linezolid works by inhibiting bacterial protein synthesis at the ribosomal level, leading to bacterial growth suppression and cell death. It is highly effective against Gram-positive cocci and aerobic Gram-positive bacteria, making it suitable for hospital-acquired infections, skin and soft tissue infections, pneumonia, septicemia, and complicated infections.

Each vial contains:

• Linezolid BP – 600 mg

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) infusion.

Linezolid for Injection is indicated for:

1. Serious Gram-positive infections including:

   • Methicillin-resistant Staphylococcus aureus (MRSA) infections

   • Vancomycin-resistant Enterococci (VRE) infections

   • Skin and soft tissue infections

   • Pneumonia (community-acquired and hospital-acquired)

   • Septicemia and bacteremia

2. Complicated infections resistant to standard antibiotics

3. Empirical therapy for severe Gram-positive infections in hospitalized patients

4. Alternative therapy for patients allergic to penicillin or glycopeptides

• Adults: 600 mg IV every 12 hours

• Children: 10 mg/kg every 8–12 hours (as per pediatric guidelines)

• Route: IV infusion over 30–120 minutes

• Dose adjustments may be required in renal impairment

• Should be administered under medical supervision

• Vials: 600 mg per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 600mg

Somatropin for Injection BP

Somatropin for Injection BP is a recombinant human growth hormone (rhGH) used for growth hormone deficiency and other growth-related disorders. It is a biosynthetic form of endogenous growth hormone that stimulates linear growth, protein synthesis, and overall metabolism in children and adults.

This sterile injectable formulation is intended for subcutaneous or intramuscular administration under specialist supervision, making it suitable for pediatric endocrinology, adult hormone replacement therapy, and other related clinical applications.

Each vial contains:

• Somatropin BP – 5 IU / 10 IU / 15 IU / 20 IU

• Excipients: q.s. sterile water for injection (lyophilized powder)

After reconstitution, it is ready for subcutaneous (SC) or intramuscular (IM) injection.

• Growth hormone deficiency (GHD) in children

• Turner Syndrome – short stature management

• Chronic Kidney Disease (CKD) – growth impairment

• Prader-Willi Syndrome – growth failure

• Small for Gestational Age (SGA) – failure to catch up growth

• Adult growth hormone deficiency (AGHD)

• Muscle wasting in chronic illness or catabolic states

• Short bowel syndrome (as part of combination therapy)

• Support in hormone replacement therapy protocols

• Adjunct therapy in selected metabolic and endocrine disorders

• Route: Subcutaneous (SC) or intramuscular (IM) injection

• Pediatric Dose: Typically 0.025–0.05 mg/kg/day, adjusted per growth response

• Adult Dose: Typically 0.1–0.3 mg/day, adjusted per clinical response

• Monitoring: Growth rate, IGF-1 levels, thyroid function, and glucose metabolism

⚠ Administer only under endocrinologist supervision

• Available strengths: 5 IU, 10 IU, 15 IU, 20 IU vials

• Lyophilized powder for injection

• Bulk and hospital packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 12 IU

Anti-Snake Venom (Polyvalent) for Injection BP

Anti-Snake Venom (Polyvalent) for Injection BP is a therapeutic immunoglobulin preparation used to neutralize venom from multiple venomous snake species. It is derived from equine plasma immunized with venoms of common snakes, and purified to ensure safety and efficacy.

This sterile injectable formulation is intended for intravenous administration under medical supervision, and is critical in emergency management of snakebites, preventing systemic envenomation, coagulopathy, neurotoxicity, and organ damage.

Each vial contains:

• Equine Polyclonal Immunoglobulin (Anti-Snake Venom) BP – 10 mL / 20 mL / 30 mL

• Excipients: q.s. sterile water for injection

• Envenomation by venomous snakes – including cobra, krait, Russell’s viper, and saw-scaled viper

• Management of systemic manifestations – neurotoxicity, hemotoxicity, myotoxicity

• Prevention of progression to severe complications – renal failure, hemorrhage, and cardiovascular collapse

• Adjunct therapy with supportive care in snakebite victims

• Emergency antidote in hospital and field settings

• Critical care management of high-risk envenomation cases

• Route: Intravenous (IV) infusion

• Adult Dose: 100–200 mL (1–2 vials) IV over 30–60 minutes, repeated depending on severity and clinical response

• Pediatric Dose: Weight-based, adjusted per protocol

• Monitoring: Vital signs, signs of hypersensitivity, coagulation profile, and systemic response

⚠ Administer only under medical supervision
⚠ Monitor for hypersensitivity reactions

• Available strengths: 10 mL, 20 mL, 30 mL vials

• Sterile solution for injection

• Hospital, emergency, and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 10 ml(lyo)

Linezolid IV Injection IP is a synthetic oxazolidinone antibiotic used for the treatment of serious infections caused by gram-positive bacteria, including resistant strains. It is administered intravenously and is commonly used in hospital settings when oral therapy is not suitable. Linezolid works by inhibiting bacterial protein synthesis, effectively stopping bacterial growth.

Each 100 ml contains:

• Linezolid IP – 600 mg

• Aqueous base q.s.

Linezolid IV Injection is indicated for the treatment of:

• Methicillin-resistant Staphylococcus aureus (MRSA) infections

• Vancomycin-resistant Enterococcus (VRE) infections

• Hospital-acquired and community-acquired pneumonia

• Skin and soft tissue infections

• Complicated gram-positive bacterial infections

• Dosage: As prescribed by the physician

• Route: Intravenous infusion only

• To be administered slowly over the recommended infusion duration

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• To be used under strict medical supervision

• Monitor complete blood count during prolonged therapy

• Use with caution in patients with hypertension or renal impairment

• Avoid concomitant use with MAO inhibitors unless advised by a physician

• Pack Size: 100 ml

• Packaging Type: Glass / Plastic IV bottle

• Form: Ready-to-use IV infusion

• Pharmacopoeia: IP

• Prescription Required: Yes

• Sterile: Yes

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10Days
• Packaging Details: 100 ml

Genryzon 24 mg Injection is a sterile injectable pharmaceutical formulation used under medical supervision for therapeutic purposes as prescribed by a qualified healthcare professional. It is manufactured following stringent quality standards to ensure safety, purity, and effectiveness. The injection is intended for parenteral administration and is commonly supplied in secure packaging suitable for hospital and clinical use.

• Active Ingredient:
  Genryzon – 24 mg

• Excipients:
  q.s. (as per formulation requirements)

• Dosage Form:
  Injection (Sterile)

Genryzon 24 mg Injection is used for treatment as advised by a physician in specific medical conditions where injectable therapy is required. The exact indication, dosage, and duration depend on the patient’s condition and clinical judgment of the doctor.

(To be used strictly on prescription only)

• Administered only by a trained healthcare professional

• Dosage and frequency as directed by the physician

• Not for self-administration unless advised

• Store in a cool and dry place

• Protect from light

• Do not freeze (unless specified by manufacturer)

• Keep out of reach of children

• For prescription use only

• Do not use if the packaging is damaged

• Consult a doctor before use

• Not recommended during pregnancy or breastfeeding unless prescribed

• Vial / Prefilled injection (as available)

• Securely packed to maintain sterility and stability

• Manufactured in compliance with GMP standards

• Tested for quality, safety, and efficacy

• India

Additional Information:

• Production Capacity: 200000
• Delivery Time: 10days
• Packaging Details: 24mg/1.2ml

Genryzon® Somatrogon 60 mg / 1.2 ml Pre-filled Pen Injection contains Somatrogon, a long-acting recombinant human growth hormone (r-hGH) analog designed for once-weekly administration. It is indicated for the treatment of pediatric growth hormone deficiency (GHD). The extended-acting formulation reduces injection frequency compared to daily somatropin, improving treatment adherence and convenience. The pre-filled pen ensures accurate dosing and ease of subcutaneous administration under specialist supervision.

Each 1.2 ml pre-filled pen contains:

• Somatrogon – 60 mg

• Excipients and stabilizers – q.s.

Genryzon® (Somatrogon) Injection is indicated for:

• Pediatric growth hormone deficiency (GHD)

• Children with inadequate endogenous growth hormone secretion

• Subcutaneous injection

• Once-weekly dosing

• Dose is calculated based on body weight and clinical response

• Administered using the pre-filled pen device

• Use strictly under the supervision of a pediatric endocrinologist

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• After first use, store as per manufacturer’s instructions

• Pre-filled pen injection

• Strength: 60 mg / 1.2 ml

Additional Information:

• Production Capacity: 250000
• Delivery Time: 10days
• Packaging Details: 60mg 1.2ml

Sevothem Injection contains Sevoflurane 10%, a volatile anesthetic agent used for induction and maintenance of general anesthesia. Sevoflurane provides rapid onset and recovery due to its low blood-gas partition coefficient, making it ideal for both adult and pediatric anesthesia. It is intended for use by trained anesthesia professionals in hospitals, surgical centers, and clinical settings.

• Active Ingredient:
  Sevoflurane – 10% w/v

• Excipients:
  q.s.

• Dosage Form:
  Liquid for inhalation

• Pharmacopoeial Standard:
  IP / USP

Sevothem 10% Injection is indicated for:

• Induction and maintenance of general anesthesia in adults and children

• Outpatient and inpatient surgical procedures requiring inhalational anesthesia

• Suitable for procedures requiring rapid induction and recovery

(Prescription medicine – hospital and anesthesia use only)

• Administered via inhalation using an anesthesia machine

• Dose adjusted according to patient age, weight, and clinical condition

• Only trained anesthesia professionals should administer

• Monitor vital signs, oxygenation, and ventilation during use

• Store below 30°C

• Protect from light

• Keep tightly closed in the original container

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10DAYS
• Packaging Details: 50 ML

Potassium Chloride for Injection BP

Potassium Chloride for Injection BP is a sterile, concentrated electrolyte solution used for the treatment and prevention of potassium deficiency (hypokalemia). Potassium is essential for proper nerve transmission, muscle contraction, and cardiac function.

This injectable preparation is intended for controlled intravenous administration in hospital and critical care settings when oral potassium supplementation is not possible or insufficient.

Each mL contains:

• Potassium Chloride BP – 75 mg / 100 mg / 150 mg

• Water for Injection BP

(Common concentrations: 7.45% w/v, 10% w/v, or 15% w/v; exact strength available on request.)

• Treatment and prevention of hypokalemia

• Potassium replacement during fluid and electrolyte imbalance

• Supportive therapy in critical care and post-operative patients

• Management of potassium loss due to diuretics, diarrhea, or vomiting

• Maintenance of normal cardiac and neuromuscular function

• For intravenous use only after appropriate dilution

• Must not be given by IM or IV bolus injection

• Administered by controlled IV infusion under continuous monitoring

• Dosage and infusion rate as prescribed by a healthcare professional

• Glass ampoules or vials

• Available pack sizes: 5 mL / 10 mL / 20 mL

• Bulk and institutional supply available

• Store below 25°C

• Protect from light

• Do not freeze

• Pharmacopoeia: BP (British Pharmacopoeia)

• Shelf Life: Typically 24–36 months

• Manufacturing Standards: WHO-GMP certified

• Usage Area: Hospitals, ICUs, emergency units

• Prescription Status: Prescription drug (Rx)

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 10x1 ml

Fondaparinux (PFS) 5 mg / 0.5 ml

Fondaparinux Sodium is a synthetic selective factor Xa inhibitor used as an anticoagulant to prevent and treat thromboembolic disorders. This sterile pre-filled syringe (PFS) formulation ensures accurate dosing and convenient subcutaneous administration. Fondaparinux effectively prevents deep vein thrombosis (DVT) and pulmonary embolism (PE) in high-risk surgical and medical patients, providing a predictable anticoagulant effect without the need for routine monitoring.

• Fondaparinux Sodium: 5 mg

• Excipients: Water for injection, sodium chloride, and BP/USP-grade stabilizers

Each PFS delivers a precise 5 mg dose in 0.5 ml.

• Prevention of deep vein thrombosis (DVT) in patients undergoing major orthopedic surgery (hip or knee replacement)

• Treatment of acute DVT with or without pulmonary embolism (PE)

• Prophylaxis of thromboembolic events in high-risk medical patients

• Alternative anticoagulant therapy in patients with heparin-induced thrombocytopenia (HIT)

• Administered via subcutaneous injection only

• Dose and duration depend on patient weight, clinical condition, and type of surgery

• Use under the supervision of a qualified healthcare professional

• Avoid intravenous administration

• Pre-filled syringe ensures accurate, ready-to-use dosing

• Sterile and pyrogen-free formulation

• Selective factor Xa inhibitor for predictable anticoagulant effect

• BP/USP-compliant quality

• Convenient and easy-to-administer formulation

• 0.5 ml PFS containing 5 mg fondaparinux

• Available in blister packs or cartons

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 2.5mg/0.5ml

Neostigmine + Glycopyrrolate For Injection BP

Neostigmine + Glycopyrrolate For Injection BP is a sterile injectable combination used to reverse the effects of non-depolarizing muscle relaxants after surgical procedures. Neostigmine is an acetylcholinesterase inhibitor that increases acetylcholine at the neuromuscular junction, reversing muscle relaxation. Glycopyrrolate, an anticholinergic agent, is included to counteract muscarinic side effects such as bradycardia, salivation, and gastrointestinal disturbances. This combination ensures safe and effective reversal of anesthesia-induced muscle relaxation.

• Neostigmine Methylsulfate: 0.5–2.5 mg

• Glycopyrrolate: 0.1–0.5 mg

• Excipients: Water for injection and BP/USP-grade stabilizers

Exact strengths may vary depending on manufacturer specifications.

• Reversal of non-depolarizing neuromuscular blockade after surgery

• Prevention and treatment of postoperative residual paralysis

• Supportive therapy in anesthesia recovery to restore normal muscle function

• Administered intravenously under the supervision of a qualified anesthesiologist

• Dosage depends on patient weight, degree of neuromuscular blockade, and clinical condition

• Must be used under close monitoring for cardiovascular and respiratory response

• Rapid and effective reversal of muscle relaxation

• Glycopyrrolate minimizes muscarinic side effects

• Sterile, BP-compliant, and pyrogen-free formulation

• Suitable for hospital, surgical, and clinical use

• 1 ml, 2 ml, 5 ml vials

• Prefilled syringes available on request

• Store at 2–8°C (refrigerated)

• Protect from light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 10x1 ml

Atropine + Neostigmine For Injection BP

Atropine + Neostigmine For Injection BP is a sterile injectable combination used to reverse non-depolarizing neuromuscular blockade induced during surgery. Neostigmine, an acetylcholinesterase inhibitor, increases acetylcholine at the neuromuscular junction, facilitating the restoration of muscle function. Atropine, an anticholinergic agent, counteracts muscarinic side effects such as bradycardia, excessive salivation, and gastrointestinal disturbances. This combination ensures safe and effective recovery from anesthesia.

• Neostigmine Methylsulfate: 0.5–2.5 mg

• Atropine Sulphate: 0.25–1 mg

• Excipients: Water for injection and BP/USP-grade stabilizers

Exact strengths may vary depending on manufacturer specifications.

• Reversal of non-depolarizing neuromuscular blockade after surgery

• Prevention and treatment of postoperative residual paralysis

• Supportive therapy in anesthesia recovery to restore normal muscle function

• Administered intravenously under the supervision of a qualified anesthesiologist

• Dosage depends on patient weight, degree of neuromuscular blockade, and clinical condition

• Patients should be monitored for cardiovascular and respiratory response

• Rapid and effective reversal of muscle relaxation

• Atropine minimizes muscarinic side effects

• Sterile, BP-compliant, and pyrogen-free formulation

• Suitable for hospital, surgical, and clinical use

• 1 ml, 2 ml, 5 ml vials

• Prefilled syringes available on request

• Store at 2–8°C (refrigerated)

• Protect from light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 10x1 ml

Ranibizumab Ophthalmic Pre-Filled Syringe (PFS) 0.5 mg / 0.05 ml

Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A), preventing abnormal blood vessel growth and vascular leakage in the eye. It is primarily used for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular disorders. The pre-filled syringe ensures accurate dosing, sterile administration, and improved patient safety.

• Ranibizumab: 0.5 mg

• Excipients: Buffer, stabilizers, and BP/USP-grade excipients

Each pre-filled syringe delivers 0.5 mg in 0.05 ml for intravitreal injection.

• Neovascular (wet) age-related macular degeneration (AMD)

• Diabetic macular edema (DME)

• Macular edema following retinal vein occlusion (RVO)

• Myopic choroidal neovascularization (mCNV)

• Other VEGF-mediated retinal disorders as prescribed by an ophthalmologist

• Administered via intravitreal injection by a qualified ophthalmologist

• Typical dosage: 0.5 mg once monthly; may vary based on patient condition and response

• Strict aseptic technique required during administration

• VEGF-A inhibitor for effective control of neovascularization and macular edema

• Pre-filled syringe for accurate, ready-to-use intravitreal dosing

• Sterile, pyrogen-free, and BP/USP-compliant formulation

• Supports vision preservation and slows progression of retinal diseases

• 0.05 ml PFS containing 0.5 mg Ranibizumab

• Supplied in sterile individual packs suitable for ophthalmic use

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 0.5mg/0.5ml

MUCOMIX Injection contains Acetylcysteine, a mucolytic and antidote agent used to reduce the viscosity of respiratory secretions and as a specific antidote in paracetamol (acetaminophen) overdose. It helps in breaking disulfide bonds in mucus, facilitating easier expectoration. The injection is supplied as a sterile solution for intravenous administration under medical supervision.

Each 2 ml ampoule contains:

• Acetylcysteine BP – strength as per label

• Water for Injection – q.s.

• Dosage Form: Injection

(Common concentration: 200 mg/ml – can be customized as per your product)

MUCOMIX Injection is used for:

• Management of paracetamol (acetaminophen) overdose

• As a mucolytic in respiratory conditions with thick mucus

• Chronic obstructive pulmonary disease (COPD)

• Bronchitis and pneumonia

• Supportive therapy in respiratory care

• Administered by intravenous (IV) route

• Dosage and duration as prescribed by a registered medical practitioner

• To be used under strict medical supervision

• Effective mucolytic agent

• Specific antidote for paracetamol toxicity

• BP grade formulation

• Suitable for hospital and emergency use

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Pack Size: 2 ml

• Pack Type: Ampoule

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 400mg/ 2ml

MUCOMIX Injection contains Acetylcysteine, a well-known mucolytic agent and antidote used to reduce the viscosity of thick respiratory secretions and in the management of paracetamol (acetaminophen) overdose. It works by breaking disulfide bonds in mucus, helping to clear airways effectively. The injection is supplied as a sterile solution for intravenous administration under medical supervision.

Each 5 ml ampoule contains:

• Acetylcysteine BP – strength as per label

• Water for Injection – q.s.

• Dosage Form: Injection

(Common concentration: 200 mg/ml – may be customized as per your product)

MUCOMIX Injection is indicated for:

• Treatment of paracetamol (acetaminophen) overdose

• As a mucolytic in respiratory disorders

• Chronic obstructive pulmonary disease (COPD)

• Bronchitis and pneumonia

• Conditions associated with thick mucus secretions

• For intravenous (IV) use

• Dosage and duration to be determined by a registered medical practitioner

• To be administered under medical supervision

• Effective mucolytic and antioxidant agent

• Specific antidote for paracetamol toxicity

• BP grade formulation

• Suitable for emergency and hospital use

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Pack Size: 5 ml

• Pack Type: Ampoule

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1 gm/5 ml

Glycopyrrolate 0.5 mg/5 ml and Neostigmine Methylsulfate 2.5 mg/5 ml Injection is a combination injectable medication used in anesthesia and perioperative care. Neostigmine acts as a cholinesterase inhibitor to reverse the effects of non-depolarizing muscle relaxants after surgery, while Glycopyrrolate is an anticholinergic that helps reduce associated muscarinic side effects such as bradycardia and excessive secretions. This injectable formulation is intended for intravenous or intramuscular use under the supervision of trained healthcare professionals.

• Active Ingredients:

  • Glycopyrrolate – 0.5 mg / 5 ml

  • Neostigmine Methylsulfate – 2.5 mg / 5 ml

• Excipients:
  q.s.

• Dosage Form:
  Sterile injection

This combination injection is indicated for:

• Reversal of non-depolarizing neuromuscular blockade following surgery

• Prevention of bradycardia and excessive salivation associated with Neostigmine administration

• Used in perioperative anesthesia care under physician supervision

(Prescription medicine – hospital and clinical use only)

• Administered intravenously or intramuscularly as directed by the anesthesiologist

• Dosage depends on patient condition, weight, and type of muscle relaxant used

• Must be administered by trained healthcare professionals

• Store below 25°C

• Protect from light

• Keep out of reach of children

• Use only as directed and discard unused portion if necessary

• For prescription use only

• Use with caution in patients with cardiac, respiratory, or renal disorders

• Monitor heart rate, blood pressure, and neuromuscular response during administration

• Not recommended during pregnancy unless clearly indicated

• 5 ml vial (single or multi-dose as per availability)

• Supplied with protective outer carton

• Manufactured in compliance with IP and GMP guidelines

• Tested for sterility, potency, and safety

• India

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 5 ampoules of 5ml each

Clostridium Botulinum Neurotoxin Type A 100 Units is a highly purified, sterile neurotoxin preparation used for therapeutic and aesthetic indications. It works by inhibiting acetylcholine release at the neuromuscular junction, leading to temporary muscle relaxation. The product is widely used in neurology, ophthalmology, dermatology, urology, and aesthetic medicine, and must be administered strictly by trained medical professionals.

Each vial contains:

• Clostridium Botulinum Neurotoxin Type A – 100 Units

• Human albumin and excipients – q.s.

Therapeutic Uses

• Cervical dystonia

• Blepharospasm and hemifacial spasm

• Spasticity (post-stroke, cerebral palsy)

• Chronic migraine prophylaxis

• Hyperhidrosis (axillary, palmar, plantar)

• Overactive bladder and detrusor overactivity

Aesthetic Uses

• Temporary improvement of moderate to severe facial wrinkles

• Treatment of glabellar lines, forehead lines, and crow’s feet

• Administered via intramuscular or intradermal injection

• Dose and injection sites depend on indication, muscle mass, and patient response

• Must be administered only by a qualified and trained healthcare professional

• Reconstitute with sterile 0.9% sodium chloride injection before use

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

Additional Information:

• Production Capacity: 100000
• Delivery Time: 10days
• Packaging Details: 100 UNITS

Carbetocin Injection 100 mcg/ml is a long-acting synthetic oxytocin analogue used to prevent uterine atony and postpartum hemorrhage (PPH) following childbirth, particularly after cesarean section. It produces sustained uterine contractions and helps reduce excessive bleeding after delivery. The injection is supplied as a clear, colorless sterile solution for intravenous or intramuscular administration.

Each ml contains:

• Carbetocin … 100 mcg

• Water for Injection IP/USP … q.s.

Carbetocin Injection is indicated for:

• Prevention of postpartum hemorrhage due to uterine atony

• Maintenance of uterine tone after cesarean section

• Use following vaginal delivery (as prescribed)

• Dose and route as directed by the physician

• Commonly administered as a single IV or IM injection immediately after delivery of the baby

• To be used under strict medical supervision

• Store at 2°C to 8°C (refrigerated)

• Protect from light

• Do not freeze

• Ampoule or vial

• Strength: 100 mcg/ml

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 5x1 ml vials

Clostridium Botulinum Neurotoxin Type A 50 Units is a highly purified, sterile neurotoxin preparation used for therapeutic and aesthetic indications. It acts by blocking the release of acetylcholine at the neuromuscular junction, resulting in temporary muscle relaxation. The product is widely used in neurology, ophthalmology, dermatology, urology, and aesthetic medicine, and must be administered by trained medical professionals only.

Each vial contains:

• Clostridium Botulinum Neurotoxin Type A – 50 Units

• Human albumin and excipients – q.s.

Clostridium Botulinum Neurotoxin Type A is indicated for:

Therapeutic Uses

• Blepharospasm and hemifacial spasm

• Cervical dystonia

• Spasticity associated with stroke or cerebral palsy

• Chronic migraine prophylaxis

• Hyperhidrosis (excessive sweating)

• Overactive bladder (urology use)

Aesthetic Uses

• Temporary improvement of facial wrinkles and dynamic lines

• Reduction of glabellar lines, crow’s feet, and forehead lines

• Administered by intramuscular or intradermal injection

• Dosage depends on indication, muscle group, and patient response

• Must be administered only by a qualified and trained healthcare professional

• Reconstitute with sterile 0.9% sodium chloride injection before use

• Store at 2–8°C (refrigerated)

• Do not freeze

• Protect from light

Additional Information:

• Production Capacity: 250000
• Delivery Time: 10days
• Packaging Details: 50 UNITS

Dexmedetomidine Injection USP 100 mcg/ml is a selective alpha-2 adrenergic receptor agonist used for sedation and analgesia in intensive care and procedural settings. It provides calm, cooperative sedation with minimal respiratory depression, making it suitable for use in ICUs, operating rooms, and procedural suites. The injection is supplied as a clear, colorless sterile solution for intravenous administration after dilution.

Each ml contains:

• Dexmedetomidine Hydrochloride USP equivalent to Dexmedetomidine 100 mcg

• Water for Injection USP – q.s.

Dexmedetomidine Injection is indicated for:

• Sedation of initially intubated and mechanically ventilated patients in ICU

• Procedural sedation in non-intubated patients

• Sedation during diagnostic and surgical procedures

• Adjunct to anesthesia for perioperative sedation

• Administered by intravenous infusion after dilution

• Dosage and duration as prescribed by an anesthesiologist or intensivist

• Continuous monitoring of vital signs is required

• Store below 25°C

• Protect from light

• Do not freeze

• Vial or ampoule

• Strength: 100 mcg/ml

• Pack size: As per manufacturer

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1x0.5 ml